FindTrial
Sign In

Study on the correlation between neoadjuvant chemoradiotherapy sensitivity and MMR/MSI in primary rectal cancer

Study on the correlation between neoadjuvant chemoradiotherapy sensitivity and MMR/MSI in primary rectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046100
Enrollment
Unknown
Registered
2021-05-04
Start date
2021-06-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

case series:N/A

Sponsors

The First Medical Center of the PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Definitely diagnosed as rectal cancer and has undergone radical resection of rectal cancer; 2. Tumor histopathology contains MMR/MSI test results; 3. Receive routine neoadjuvant chemoradiotherapy.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
tumor regression grading;—

Secondary

MeasureTime frame
R0 resection rate;overall response rate;—

Countries

China

Contacts

Public ContactZhang Chaojun

The First Medical Center of the PLA General Hospital

zcjdlyxzx@163.com+86 18600317036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026